ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Test the Usefulness of Magnetoencephalography (MEG) Imaging of Cognition in Children and Adolescents

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00924300
Recruitment Status : Completed
First Posted : June 18, 2009
Last Update Posted : January 31, 2018
Sponsor:
Information provided by (Responsible Party):
Tony W. Wilson, PhD, University of Nebraska

Brief Summary:
The primary objective of this protocol is to test the feasibility and utility of obtaining magnetoencephalography (MEG) recordings in healthy children and also in children who have a psychiatric or developmental disorder. Secondary objectives are to examine and compare typical and atypical motor, sensory, and cognitive functioning as recorded by MEG, and to identify subpopulation groups for which MEG may be optimal in order to establish feasibility of future hypothesis-driven MEG research.

Condition or disease
Cognition

Detailed Description:
Healthy children and those who have a psychiatric or developmental disorder will undergo MEG recording to evaluate whether such children are candidate MEG subjects. Essentially, this feasibility study will examine whether children can remain still enough, complete simple tasks, and produce neurophysiologically consistent responses that would warrant full size studies.

Study Type : Observational
Actual Enrollment : 36 participants
Observational Model: Case-Control
Time Perspective: Other
Official Title: Magnetoencephalography (MEG) and Magnetic Resonance Imaging (MRI) Studies of Typical and Atypical Cognitive Processes in Children and Adolescents
Actual Study Start Date : July 7, 2009
Actual Primary Completion Date : September 2017
Actual Study Completion Date : September 2017

Group/Cohort
patients
children and/or adolescents with psychiatric disorder
controls
typically-developing children/adolescents



Primary Outcome Measures :
  1. MEG activation [ Time Frame: course of study ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   4 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
children and adolescents with or without a psychiatric disorder
Criteria

Inclusion Criteria:

  • May or may not have a psychiatric or developmental disorder diagnosis.
  • Outpatient at study entry.
  • Age 4-18 (inclusive).
  • Male or female.
  • Have ability to sit still for 5 minutes or longer.
  • Have ability to comply with basic instructions.
  • Provide written informed assent if willing and able, per local IRB requirements before any study specific procedures are performed.
  • Parent or legal guardian provide written informed consent before any study specific procedures are performed.

Exclusion Criteria:

  • Ferrous metal permanently attached on or implanted in their body.
  • Metal braces on teeth (i.e. Invisalign braces and cavity fillings are permitted).
  • Has major medical condition, including cancer or hepatitis.
  • Has confounding multiple psychiatric and/or developmental diagnoses, as judged by the principal or co-investigator.
  • Known history or diagnosis of alcohol or substance abuse/dependence.
  • Unable or unwilling to comply with the protocol.
  • Anyone deemed as not appropriate for study participation, as deemed by the principal investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00924300


Locations
United States, Nebraska
University of Nebraska MEdical Center
Omaha, Nebraska, United States, 68198
Sponsors and Collaborators
University of Nebraska
Investigators
Principal Investigator: Tony W Wilson, Ph.D. University of Nebraska

Responsible Party: Tony W. Wilson, PhD, Associate Professor, University of Nebraska
ClinicalTrials.gov Identifier: NCT00924300     History of Changes
Other Study ID Numbers: 217-09-FB
First Posted: June 18, 2009    Key Record Dates
Last Update Posted: January 31, 2018
Last Verified: January 2018

Keywords provided by Tony W. Wilson, PhD, University of Nebraska:
feasibility of MEG in pediatric populations